Skip to main content

VTRS

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

VTRS Price
Price Chart

Forward-looking statistics

Beta
0.74
Risk
35.03%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees25K
Market cap$12.5B

Fundamentals

Enterprise value$23.9B
Revenue$14.3B
Revenue per employee
Profit margin-26.45%
Debt to equity92.38

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.18
Dividend per share$0.48
Revenue per share$12.02
Avg trading volume (30 day)$138M
Avg trading volume (10 day)$112M
Put-call ratio

Macro factor sensitivity

Growth+3.2
Credit-0.9
Liquidity-1.6
Inflation+0.5
Commodities+1.0
Interest Rates-0.1

Valuation

Dividend yield5.20%
PEG Ratio3.49
Price to sales0.76
P/E Ratio3.49
Enterprise Value to Revenue1.67
Price to book0.71

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend dayMay 23, 2025

News

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.

Zacks Investment Research (June 9, 2025)
Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars

Viatris Inc. VTRS on Thursday, released data from Phase 3 study evaluating the contraceptive efficacy and safety of XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential.

Benzinga (May 8, 2025)
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.

CNBC Television (April 9, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free